These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 32667262)
1. The changing landscape of stage III lung cancer: a literature review. Patel M; Bruno D; Grubb W; Biswas T Expert Rev Anticancer Ther; 2020 Aug; 20(8):675-686. PubMed ID: 32667262 [TBL] [Abstract][Full Text] [Related]
3. Unmet Clinical Need in the Management of Locally Advanced Unresectable Lung Cancer: Treatment Strategies to Improve Patient Outcomes. Rajappa S; Sharma S; Prasad K Adv Ther; 2019 Mar; 36(3):563-578. PubMed ID: 30693419 [TBL] [Abstract][Full Text] [Related]
4. Durvalumab for the treatment of non-small cell lung cancer. Murakami S Expert Rev Anticancer Ther; 2019 Dec; 19(12):1009-1016. PubMed ID: 31782989 [No Abstract] [Full Text] [Related]
5. Advances in the Treatment of Stage III Non-Small Cell Lung Cancer. Myall NJ; Das M Clin Chest Med; 2020 Jun; 41(2):211-222. PubMed ID: 32402357 [TBL] [Abstract][Full Text] [Related]
6. Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience. Botticella A; Mezquita L; Le Pechoux C; Planchard D Ther Adv Respir Dis; 2019; 13():1753466619885530. PubMed ID: 31686616 [TBL] [Abstract][Full Text] [Related]
7. Role of immunotherapy in stage III nonsmall cell lung cancer. Wrona A Curr Opin Oncol; 2019 Jan; 31(1):18-23. PubMed ID: 30489337 [TBL] [Abstract][Full Text] [Related]
8. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group. Hallqvist A; Wagenius G; Rylander H; Brodin O; Holmberg E; Lödén B; Ewers SB; Bergström S; Wichardt-Johansson G; Nilsson K; Ekberg L; Sederholm C; Nyman J Lung Cancer; 2011 Feb; 71(2):166-72. PubMed ID: 20541833 [TBL] [Abstract][Full Text] [Related]
9. Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer prior to the approval of durvalumab. Fukui T; Hosotani S; Soda I; Ozawa T; Kusuhara S; Kakegawa MI; Kasajima M; Hiyoshi Y; Igawa S; Yokoba M; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Ishiyama H; Naoki K Thorac Cancer; 2020 Apr; 11(4):1005-1014. PubMed ID: 32057187 [TBL] [Abstract][Full Text] [Related]
10. Is There a Survival Benefit in Patients With Stage IIIA (N2) Non-small Cell Lung Cancer Receiving Neoadjuvant Chemotherapy and/or Radiotherapy Prior to Surgical Resection: A Systematic Review and Meta-analysis. Xu YP; Li B; Xu XL; Mao WM Medicine (Baltimore); 2015 Jun; 94(23):e879. PubMed ID: 26061306 [TBL] [Abstract][Full Text] [Related]
11. Current status of immune checkpoint inhibition in early-stage NSCLC. Vansteenkiste J; Wauters E; Reymen B; Ackermann CJ; Peters S; De Ruysscher D Ann Oncol; 2019 Aug; 30(8):1244-1253. PubMed ID: 31143921 [TBL] [Abstract][Full Text] [Related]